Sensus Healthcare reported strong Q3 results with 127% YoY revenue growth and EPS of $0.07, indicating effective management and demand recovery. The new FDA contracts and a major deal with Platinum Dermatology promise recurring revenue and reduced client concentration risk. Despite these positive developments, the stock price saw minimal movement, suggesting it may be undervalued. The potential for a 150% upside over the next five years makes it an attractive investment opportunity.